Antihemorrhagic drug - Thrombotargets Corp

Trombosis
TT 103MH

[ Cerrar ]

Discovery & Pipeline

Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms (), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.

Antihemorrhagic drug

Know the TT-103MH by Thrombotargets. The antihemorrhagic drug that Thrombotargets' team is developing for bleeding treatments. Revolutionary topical administration. Know the characteristic of this antihemorrhagic drug.

Hemostatic agents

The novel and most revolutionary hemostatic agents. Thrombotargets has developed the TT-103MH, the human recombinant antibleeding protein that has been designed to treat all kind of bleeding disorders

Haemostatic drug

Know the novel TT-103MH, the haemostatic drug by Thrombotargets. It is a new way for treating topically all kinds of bleeding. See here the characteristics of this revolutionary haemostatic drug.

Antihemorrhagic agents

Thrombotargets is developing new drug for hemostasis, atherosclerosis, aging and thrombosis. Know the revolutionary antihemorrhagic agents for all kind of bleeding treatments.

Thrombotargets is developing TT- 103MH, a novel and significantly radical approach for the treatment of bleeding disorders. Using a topical formulation TT-103MH, will be effective in treating:

• Healthy subjects
• Haemophilic patients
• Inherited and acquired coagulation and platelet disorders
• Haemorrhages induced by anticoagulant and antiplatelet drugs.